Global Information
회사소개 | 문의 | 위시리스트

간질 : 역학 및 환자 기반 시장 예측, 치료 알고리즘, 출시 및 개발중인 약제 분석

Epilepsy Forecast and Market Analysis to 2035

리서치사 Datamonitor Healthcare
발행일 2018년 07월 상품 코드 365216
페이지 정보 영문 345 Pages
가격
US $ 22,000 ₩ 27,009,000 PDF by E-mail (Single User License)
US $ 107,800 ₩ 132,346,000 PDF by E-mail (Global License)


간질 : 역학 및 환자 기반 시장 예측, 치료 알고리즘, 출시 및 개발중인 약제 분석 Epilepsy Forecast and Market Analysis to 2035
발행일 : 2018년 07월 페이지 정보 : 영문 345 Pages

간질(Epilepsy) 치료제 시장에 대해 조사 분석했으며, 시장 예측, 치료, 역학, 출시 및 개발중인 약제 동향 등의 정보를 전해드립니다.

1. 예측 : 간질

  • 주요 요약
  • 시장 개요와 동향
  • 시장 정의와 조사 방법
  • Aptiom/Zebinix(eslicarbazepine)
  • Fycompa(perampanel)
  • Lyrica(pregabalin)
  • Potiga/Trobalt(ezogabine/retigabine)
  • Rikelta(brivaracetam)
  • Vimpat(lacosamide)
  • 1차 조사 방법

2. 치료 : 간질

  • 주요 요약
  • 1차 조사 방법
  • 질환의 정의와 진단
  • 환자 세분화
  • 현재 치료 옵션
  • 치료 동향
  • 미충족 요구

3. 역학 : 간질

  • 주요 요약
  • 질환 배경
  • 정보 출처와 조사 방법
  • 예측
  • 역학자의 분석
  • 강점과 제약
  • 부록

4. 출시된 약제 : 간질

  • 주요 요약
  • 제품 개요
  • 기타 출시된 약제
  • 제품 프로파일 : Aptiom
  • 제품 프로파일 : Banzel
  • 제품 프로파일 : Briviact
  • 제품 프로파일 : Fycompa
  • 제품 프로파일 : Keppra, Keppra XR
  • 제품 프로파일 : Lamictal, Lamictal XR
  • 제품 프로파일 : Lyrica
  • 제품 프로파일 : Onfi
  • 제품 프로파일 : Potiga
  • 제품 프로파일 : Vimpat

5. 파이프라인 : 간질

  • 주요 요약
  • 임상 파이프라인 개요
  • 제품 프로파일(후기 단계) : Epidiolex
  • 제품 프로파일(후기 단계) : ganaxolone
KSM 16.08.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

OVERVIEW:

Epilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological Disorders and Stroke as causing "strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness." There are many possible causes of epilepsy including cerebrovascular disease, brain injury, abnormal brain development, central nervous system infection, tumors, and genetic factors.

MARKET SNAPSHOT:

  • Label expansions will drive uptake of newer brands, sustaining the epilepsy market by countering widespread genericization.
  • Levetiracetam, valproate formulations, lamotrigine, and carbamazepine constitute the mainstay of epilepsy treatment.
  • Although approximately 70% of epilepsy patients respond to treatment, the number of prevalent cases of active epilepsy remains high.
  • UCB will continue to dominate the epilepsy market with key drugs Keppra and Vimpat.
  • With positive Phase III data in LGS, Epidiolex is proving to be the therapy of choice for refractory childhood epilepsy.

TABLE OF CONTENTS

FORECAST: EPILEPSY (Published on 11 July 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • APTIOM/ZEBINIX (ESLICARBAZEPINE)
  • BANZEL/INOVELON (RUFINAMIDE)
  • BRIVIACT (BRIVARACETAM)
  • EPIDIOLEX (CANNABIDIOL)
  • FYCOMPA (PERAMPANEL)
  • KEPPRA/KEPPRA XR (LEVETIRACETAM)
  • LAMICTAL/LAMICTAL XR (LAMOTRIGINE)
  • LYRICA (PREGABALIN)
  • ONFI (CLOBAZAM)
  • VIMPAT (LACOSAMIDE)
  • PRIMARY RESEARCH METHODOLOGY

TREATMENT: EPILEPSY (Published on 31 May 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • TREATMENT DYNAMICS
  • UNMET NEEDS IN EPILEPSY

EPIDEMIOLOGY: EPILEPSY (Published on 18 July 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: EPILEPSY (Published on 23 May 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: APTIOM
  • PRODUCT PROFILE: BANZEL
  • PRODUCT PROFILE: BRIVIACT
  • PRODUCT PROFILE: FYCOMPA
  • PRODUCT PROFILE: KEPPRA AND KEPPRA XR
  • PRODUCT PROFILE: LAMICTAL AND LAMICTAL XR
  • PRODUCT PROFILE: LYRICA
  • PRODUCT PROFILE: ONFI
  • PRODUCT PROFILE: VIMPAT

PIPELINE: EPILEPSY (Published on 02 October 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • LATEST ANALYST OPINION
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): EPIDIOLEX
  • PRODUCT PROFILE (LATE STAGE): GANAXOLONE

LIST OF FIGURES

  • Figure 1: Epilepsy market sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Growth dynamics of the epilepsy market across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 3: Epilepsy market sales across the US, Japan, and five major EU markets, by epilepsy subtype, 2016-25
  • Figure 4: Epilepsy market sales across the US, Japan, and five major EU markets, by drug type, 2016-25
  • Figure 5: Sales of selected competing POS brands across the US, Japan, and five major EU markets, 2016-25
  • Figure 6: Sales of selected competing LGS brands across the US, Japan, and five major EU markets, 2016-25
  • Figure 7: Methodology flow for Datamonitor Healthcare's epilepsy patient-based forecast
  • Figure 8: Price sources and calculations, by country
  • Figure 9: Aptiom/Zebinix sales for epilepsy across the US and five major EU markets, by country, 2016-25
  • Figure 10: Banzel/Inovelon sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 11: Briviact sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 12: Epidiolex sales for epilepsy across the US and five major EU markets, by country, 2016-25
  • Figure 13: Fycompa sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 14: Keppra/Keppra XR sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 15: Lamictal/Lamictal XR sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Lyrica sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 17: Onfi sales for epilepsy in the US, 2016-25
  • Figure 18: Vimpat sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 19: Classification of epilepsy seizures
  • Figure 20: Diagnosis rates for epilepsy in the US, Japan, and five major EU markets, by country
  • Figure 21: Segmentation of epilepsy patients by seizure subtype in the US, Japan, and five major EU markets, by country
  • Figure 22: Segmentation of epilepsy patients by treatment response in the US, Japan, and five major EU markets, by country
  • Figure 23: Drug treatment rate for epilepsy in the US, Japan, and five major EU markets, by country
  • Figure 24: Levels of efficacy and effectiveness evidence supporting use of AEDs in epilepsy subpopulations*
  • Figure 25: First- and second-line therapies recommended for epilepsy subpopulations in the UK
  • Figure 26: Top four overall drug treatments across the US, Japan, and five major EU markets, by epilepsy subtype
  • Figure 27: Average ranking of drugs across the US, Japan, and five major EU markets for all epilepsy subtypes
  • Figure 28: Top five drug treatments for treatment-responsive POS in the US, Japan, and five major EU markets, by country
  • Figure 29: Top five drug treatments for treatment-refractory POS in the US, Japan, and five major EU markets, by country
  • Figure 30: Top five drug treatments for treatment-responsive generalized seizures in the US, Japan, and five major EU markets, by country
  • Figure 31: Top five drug treatments for treatment-refractory generalized seizures in the US, Japan, and five major EU markets, by country
  • Figure 32: Compliance rates of epilepsy patients in the US, Japan, and five major EU markets, by country, seizure type, and responsiveness to treatment
  • Figure 33: Key unmet needs for epilepsy, 2016
  • Figure 34: Trends in diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets, 2017-37
  • Figure 35: Aptiom for epilepsy - SWOT analysis
  • Figure 36: Datamonitor Healthcare's drug assessment summary for Aptiom in epilepsy
  • Figure 37: Datamonitor Healthcare's drug assessment summary for Aptiom in epilepsy
  • Figure 38: Banzel for epilepsy - SWOT analysis
  • Figure 39: Datamonitor Healthcare's drug assessment summary for Banzel in epilepsy
  • Figure 40: Datamonitor Healthcare's drug assessment summary for Banzel in epilepsy
  • Figure 41: Briviact for epilepsy - SWOT analysis
  • Figure 42: Datamonitor Healthcare's drug assessment summary for Briviact in epilepsy
  • Figure 43: Datamonitor Healthcare's drug assessment summary for Briviact in epilepsy
  • Figure 44: Fycompa for epilepsy - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary for Fycompa in epilepsy
  • Figure 46: Datamonitor Healthcare's drug assessment summary for Fycompa in epilepsy
  • Figure 47: Keppra and Keppra XR for epilepsy - SWOT analysis
  • Figure 48: Datamonitor Healthcare's drug assessment summary for Keppra in epilepsy
  • Figure 49: Datamonitor Healthcare's drug assessment summary for Keppra in epilepsy
  • Figure 50: Lamictal/Lamictal XR for epilepsy - SWOT analysis
  • Figure 51: Datamonitor Healthcare's drug assessment summary for Lamictal in epilepsy
  • Figure 52: Datamonitor Healthcare's drug assessment summary for Lamictal in epilepsy
  • Figure 53: Lyrica for epilepsy - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary for Lyrica in epilepsy
  • Figure 55: Datamonitor Healthcare's drug assessment summary for Lyrica in epilepsy
  • Figure 56: Onfi for epilepsy - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary for Onfi in epilepsy
  • Figure 58: Datamonitor Healthcare's drug assessment summary for Onfi in epilepsy
  • Figure 59: Vimpat for epilepsy - SWOT analysis
  • Figure 60: Datamonitor Healthcare's drug assessment summary for Vimpat in epilepsy
  • Figure 61: Datamonitor Healthcare's drug assessment summary for Vimpat in epilepsy
  • Figure 62: Epidiolex for epilepsy - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary for Epidiolex in epilepsy
  • Figure 64: Datamonitor Healthcare's drug assessment summary for Epidiolex in epilepsy
  • Figure 65: Ganaxolone for epilepsy - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary for ganaxolone in epilepsy
  • Figure 67: Datamonitor Healthcare's drug assessment summary for ganaxolone in epilepsy

LIST OF TABLES

  • Table 1: Epilepsy market sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Epilepsy market sales across the US, Japan, and five major EU markets, by epilepsy subtype ($m), 2016-25
  • Table 3: Epilepsy market sales across the US, Japan, and five major EU markets, by drug type ($m), 2016-25
  • Table 4: Sales of selected competing POS brands across the US, Japan, and five major EU markets ($m), 2016-25
  • Table 5: Sales of selected competing LGS brands across the US, Japan, and five major EU markets ($m), 2016-25
  • Table 6: Exchange rates used for calculating prices
  • Table 7: Estimated patent expiry/loss of exclusivity dates for key marketed brands in epilepsy, by country, 2016-25
  • Table 8: Estimated launch and approval dates for key products in epilepsy, by country, 2016-25
  • Table 9: Aptiom/Zebinix sales for epilepsy across the US and five major EU markets, by country ($m), 2016-25
  • Table 10: Banzel/Inovelon sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 11: Briviact sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 12: Epidiolex sales for epilepsy across the US and five major EU markets, by country ($m), 2016-25
  • Table 13: Fycompa sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 14: Keppra/Keppra XR sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 15: Lamictal/Lamictal XR sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 16: Lyrica sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 17: Onfi sales for epilepsy in the US ($m), 2016-25
  • Table 18: Vimpat sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 19: Neurologists surveyed for the epilepsy primary research study, 2016
  • Table 20: Neurologists surveyed for the epilepsy primary research study, 2016
  • Table 21: Diagnosis rates for epilepsy in the US, Japan, and five major EU markets, by country (%)
  • Table 22: Segmentation of epilepsy patients by seizure subtype in the US, Japan, and five major EU markets, by country (%)
  • Table 23: Segmentation of epilepsy patients by treatment response in the US, Japan, and five major EU markets, by country (%)
  • Table 24: Drug treatment rate for epilepsy in the US, Japan, and five major EU markets, by country (%)
  • Table 25: Leading therapies for epilepsy
  • Table 26: Leading drug treatments according to patient share across the US, Japan, and five major EU markets, by epilepsy subtype (%)
  • Table 27: Drug treatments for treatment-responsive POS in the US, Japan, and five major EU markets, by country (%)
  • Table 28: Drug treatments for treatment-refractory partial-onset seizures in the US, Japan, and five major EU markets, by country (%)
  • Table 29: Drug treatments for treatment-responsive generalized seizures in the US, Japan, and five major EU markets, by country (%)
  • Table 30: Drug treatments for treatment-refractory generalized seizures in the US, Japan, and five major EU markets, by country (%)
  • Table 31: Compliance rates of epilepsy patients in the US, Japan, and five major EU markets, by country, seizure type, and responsiveness to treatment (%)
  • Table 32: Sources used for the epidemiological analysis of epilepsy in the US, Japan, and major EU markets, by country
  • Table 33: Diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 34: Key marketed drugs for epilepsy
  • Table 35: Aptiom epilepsy indication approvals
  • Table 36: Aptiom drug profile
  • Table 37: Aptiom pivotal trial data in epilepsy
  • Table 38: Ongoing late-phase trials
  • Table 39: Banzel drug profile
  • Table 40: Banzel pivotal trial data in epilepsy
  • Table 41: Safety profile for Banzel in epilepsy
  • Table 42: Briviact drug profile
  • Table 43: Briviact pivotal trial data in epilepsy
  • Table 44: Fycompa epilepsy indication approvals
  • Table 45: Fycompa drug profile
  • Table 46: Fycompa pivotal trial data in epilepsy
  • Table 47: Ongoing late-phase trials
  • Table 48: Keppra/Keppra XR epilepsy indication approvals
  • Table 49: Keppra and Keppra XR drug profile
  • Table 50: Keppra pivotal trial data in epilepsy
  • Table 51: Safety profile for Keppra in epilepsy
  • Table 52: Keppra XR pivotal trial data in epilepsy
  • Table 53: Safety profile for Keppra XR in epilepsy
  • Table 54: Lamictal/Lamictal XR epilepsy indication approvals
  • Table 55: Lamictal and Lamictal XR drug profile
  • Table 56: Lamictal pivotal trial data in epilepsy
  • Table 57: Safety profile for Lamictal in epilepsy
  • Table 58: Lamictal XR pivotal trial data in epilepsy
  • Table 59: Safety profile for Lamictal XR in epilepsy
  • Table 60: Lyrica drug profile
  • Table 61: Lyrica pivotal trial data in epilepsy
  • Table 62: Safety profile for Lyrica in epilepsy
  • Table 63: Pfizer late-phase trial data in partial-onset epilepsy
  • Table 64: Lyrica ongoing late-phase trials for pediatric and adult epilepsy indications
  • Table 65: Onfi drug profile
  • Table 66: Onfi pivotal trial data in epilepsy
  • Table 67: Safety profile for Onfi in epilepsy
  • Table 68: Vimpat epilepsy indication approvals
  • Table 69: Vimpat drug profile
  • Table 70: Vimpat pivotal trial data in epilepsy
  • Table 71: Safety profile for Vimpat in epilepsy
  • Table 72: Vimpat late-phase trial data in epilepsy
  • Table 73: Vimpat ongoing late-phase clinical trials as monotherapy in epilepsy
  • Table 74: Pipeline products in development for epilepsy
  • Table 75: ZX008 Phase III trial in Dravet syndrome
  • Table 76: Epidiolex drug profile
  • Table 77: Epidiolex Phase II/III data in epilepsy
  • Table 78: Epidiolex physician-led expanded access program data
  • Table 79: Epidiolex Phase III trials in Dravet syndrome, tuberous sclerosis complex, and infantile spasms
  • Table 80: Ganaxolone drug profile
  • Table 81: Ganaxolone Phase II/III data in epilepsy
Back to Top
전화 문의
F A Q